摘要
目的探讨新辅助化疗对子宫内膜癌患者疗效及血清VEGF及MMP-9的影响.方法将84例子宫内膜癌患者随机分为两组,研究组患者术前使用新辅助化疗,术后常规化疗,对照组患者术后常规化疗.比较两组患者治疗前后血清VEGF、MMP-9、肿瘤标记物CA125及CA19-9的变化,观察手术时长和术中失血量、术后18个月内两组患者的复发及生存情况,进行比较分析.结果研究组治疗后血清VEGF,MMP-9及CA125的水平明显低于对照组(P<0. 05).术后18个月,研究组复发率为11. 9%,对照组复发率为26. 1%,研究组复发率明显低于对照组(P<0. 05),两组术后生存率均为100%.结论子宫内膜癌患者实施新辅助化疗后再行手术,血清VEGF及MMP-9水平降低更显著,术后复发率更低.
Objective To investigate the effect of neoadjuvant chemotherapy on serum VEGF and MMP-9 in patients with endometrial carcinoma.Method A total of 84 patients with endometrial carcinoma were divided into two groups,the treatment group and the control group.Comparative analysis of changes of serum VEGF,MMP-9 and CEA in the two groups before and after treatment was performed.The operation index and the postoperative 18 months survival and the recurrence rate in the two groups were compared.Results The operation time in treatment group was significantly shorter than that in control group(P<0.05).After treatment,the serum VEGF,MMP-9 and CEA125 of patients in the treatment group were significantly lower than those in the control group(P<0.05).The recurrence rate of the study group was 11.9%,which was lower than that of control group(26.1%)postoperative 18 months(P<0.05).The survival rates in two groups were 100%.Conclusion The patients with endometrial cancer after receiving the neoadjuvant chemotherapy showed good effect.The method can effectively reduce the operation time,reduce the serum VEGF,MMP-9 and CEA125 levels of patients,reduce the postoperative recurrence rate and improve survival rate.
作者
闫丽娜
杨滢
丁建龙
闫铭峰
范志刚
Yan Lina;Yang Ying;Ding Jianlong;Yan Mingfeng;Fan Zhigang(Affiliated Hospital of Medical College,Xi'an Jiaotong University,Hanzhong 723000,China)
出处
《北华大学学报（自然科学版）》
CAS
2019年第1期82-85,共4页
Journal of Beihua University（Natural Science）
基金
陕西省科技攻关资助项目(2014SF037)
关键词
子宫内膜癌
血管内皮生长因子
基质金属蛋白酶9
endometrial carcinoma
vascular endothelial growth factor
matrix metalloproteinase 9
